Literature DB >> 30610005

Stromal morphological changes and immunophenotypic features of precancerous lesions and hepatocellular carcinoma.

Dingbao Chen1,2, Zhao Li1, Weihua Zhu1, Qian Cheng1, Qiujing Song2, Lihua Qian2, Ji-Ye Zhu3.   

Abstract

AIMS: To evaluate stromal histopathological features and immunostaining expression for differential diagnosis of low- and high-grade dysplastic nodules (HGDN) to early and progressed hepatocellular carcinomas (eHCC, pHCC). MATERIALS: We evaluated sinusoid capillarisation (SC), solitary artery (SA), ductular reaction (DR), stromal invasion and expression of six biomarkers (GPC3, HSP70, GS, CD34, CK19, EpCAM) in a series of 97 cases.
RESULTS: Stromal morphological changes, including SC, DR and SA, exhibited significant differences in differential diagnosis. In one indicator, SC had the best sensitivity (90.00%) and accuracy (85.42%), and SA had the best specificity at 88.89 %. In combinations, SC +and SA +were favourable and optimal. The immunoreactivity of GPC3, HSP70 and GS increased significantly in line with the stepwise progression of hepatocarcinogenesis.
CONCLUSIONS: Stromal histopathology features are useful for diagnosing HGDN, eHCC and small HCC. The immunostaining panel of GPC3, HSP70 and GS can also be supplementary. © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  carcinogenesis; early hepatocellular carcinoma; hepatocellular carcinoma; high-grade dysplastic nodule; immunohistochemistry

Mesh:

Substances:

Year:  2019        PMID: 30610005     DOI: 10.1136/jclinpath-2018-205611

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  1 in total

1.  Preoperative determination of pathological grades of primary single HCC: development and validation of a scoring model.

Authors:  Zhao-Xiang Ye; Wen Shen; Kun Zhang; Wen-Cui Li; Shuang-Shuang Xie; Li-Ying Lin; Zhi-Wei Shen
Journal:  Abdom Radiol (NY)       Date:  2022-07-17
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.